## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	) Examiner: McKelvey, Terry Alan
Kevin P. BAKER, et al.	) Art Unit: 1636 )
Application Serial No. 10/006,856	) Confirmation No: 8365
Filed: December 6, 2001	) Attorney's Docket No. 39780-2830 P1C14
For: SECRETED AND	Customer No. 35489
TRANSMEMBRANE	)
POLYPEPTIDES AND NUCLEIC	)
ACIDS ENCODING THE SAME	)

EXPRESS MAIL LABEL NO.: EL 976 545 064 US

DATE MAILED: JUNE 29, 2005

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

## MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

			s, or so considered to co, material to parental my action in § 1.00.		
This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):					
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  OR		
		(2)	It is being filed within 3 months of entry of a national stage OR		
		(3)	It is being filed before the mail date of the first Office Action on the merits		

17/06/2005 WABDELR1 00000050 081641

01 FC:1806

		OR  It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.			
	2. $\S1.97(c)$ . If this statement is being filed after the latest of: (1) three months beyond the te of a national application; (2) three months beyond the date of entry of the national set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Office in the merits, but before the mailing date of the earlier of a final office action under $\S1.113$ are of allowance under $\S1.311$ , then:				
		a certification as specified in §1.97(e) is provided below; or			
		a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.			
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:				
	A.	a certification as specified in §1.97(e) is completed below; and			
	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and			

Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39780-2830 P1C14).

Respectfully submitted,

a fee of \$130.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with

the payment of other papers filed together with this statement.

Dated: June 28, 2005

C.

 $\boxtimes$ 

By: Barrie D. Greene (Reg. No. 46,740)

## HELLER EHRMAN WHITE & McAULIFFE LLP

275 Middlefield Road Menlo Park, CA 94025-3506

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

SV 2131171 v1 (39780.2830)

Form PTO-1449 SUPPLEMENTAL		Attorney's Docket No. 39780-2830 P1C14		Application Serial No. 10/006,856				
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT			10/	000,030				
THE RESERVE STATEMENT A				1 11	P. BAKER,	et al.		
			<u> </u>	Filing Date:		oup Art Uni	t:	
	(use sev	eral sheets	if necessary)	December 6, 2001	163	36	_	-
				PATENT DOCUMENTS				
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Filing Date	
Initials	No.						(if appropr	riate)
. 4. 10	<u>                                     </u>				Balaisi a ta ta a ta a ta a	LANGE OF COMMENT		
	L D. C			GN PATENT DOCUMENTS		Ta.,	· ·	
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Transla	
Illitials	NO.					<u> </u>	YES	NO
				THER DOCUMENTS	orda i trasi.		(株式 事業) おしない。	Sworth vil
			<ul> <li>Color Della Color Color</li></ul>	THER DOCUMENTS thor, title, date, pertinent pages, etc	1			
Examiner	Ref.	Title	Applied to the set of	inor, inc, unic, periment puges, etc			198, 2 8, 12 1 9, 2	yearn mae'r nau'r l
Initials	No.							
	1.	Goldwaser	, Itzhak, et al., "L-Glutar	nic Acid γ-Monohydroxamate", The	Journal of B	iomedical Cl	nemistry, Vo	1. 274,
		No. 37, pp	26617-26624, September	er 10, 1999.				
	2.		S., et al., "HER-2/neu Bre	eat Cancer Predictive Testing", Oatho	ology Associa	ates Medical	Laboratores	-
		(1999).  Hyman, E., et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer <sup>1,2</sup> ", Cancer						
	3.			Amplification on Gene Expression I	Patterns in Br	east Cancer'	<sup>2</sup> ", Cancer	
	4.		- <u>62</u> :6240-6245 (2002).	ce That Glucose Metabolism Regula	taa I antin Ca	anation from	Cultura d Da	
	4.			139, No. 2, pp 551-558 (1998).	ies Lepun Se	cretion from	Cultured Ka	ιτ
	5.			of Metformin and Vanadium on Leg	ntin Secretion	from Cultur	ed Rat	
				ol. 8, No. 7, pp 530-539, October 200		i mom cuna	ou rui	
	6.	Orntoft, T.	F., et al., "Genome-wide	Study of Gene Copy Numbers, Tran	scripts, and			
				sitional Cell Carcinomas", Molecula				
	7.	Pollack, J.R., et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the						
		Transcriptional Program of Human Breast Tumors", PNAS – 99(20):12963-12968 (2002).						
	8.	Sandouk, Tagrid, et al., "The Antidiabetic Agent Pioglitazone Increases Expression of Glucose Transporters in 3T3-						
		F442A Cells by Increasing Messenger Ribonucleic Acid Transcript Stability", Endocrinology, Vol. 133, No. 1, pp 352-359 (1993).						
	9.	Tafuri, Sherrie R., "Troglitazone Enhances Differentiation, Basal Glucose Uptake, and Glut 1 Protein Levels in						
		3T3-L1 Adipocytes", Endocrinology, Vol. 137, No. 11, pp 4706-4712 (1996).						
						·	<del>,</del>	
	<b>_</b>							
	-							
	<del> </del>					<del></del>		

<b>EXAMINER:</b>	/Nancy Vogel/	DATE CONSIDERED:	12/11/2008
<b>EXAMINER:</b>	Initial if citation considered, whether or not the citation	n conforms with MPEP 609. [	Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2131171 v1